Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2CNS 1

Conditions

Sarcoma, Ewing 2Osteosarcoma 2Rhabdoid Tumor 1Osteosarcoma Recurrent 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Ifosfamide 30Methotrexate 29Doxorubicin 26Cyclophosphamide 24Cisplatin 22Filgrastim 18Etoposide 17Gemcitabine 16Leucovorin 14Magnetic Resonance Spectroscopy 11Temozolomide 10Specimen Handling 10cabozantinib 9apatinib 9X-Rays 9Carboplatin 9fludarabine 8Radiotherapy 8Nivolumab 8Neoadjuvant Therapy 8Irinotecan 8Granulocyte Colony-Stimulating Factor 8Drug Therapy 8Docetaxel 8Zoledronic Acid 7Vincristine 7Sirolimus 7Phantoms, Imaging 7Biopsy 7mifamurtide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Osteosarcoma × Eflornithine × Sarcoma × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT07321912 2026-05-26

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Milton S. Hershey Medical Center

Phase 2 Recruiting
406 enrolled
Sarcoma

Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡